1-methylethyl 5-chloro-6-[(1-methylethyl)oxy]-3-pyridinecarboxylate | 187401-46-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-methylethyl 5-chloro-6-[(1-methylethyl)oxy]-3-pyridinecarboxylate
• 英文别名: isopropyl 5-chloro-6-isopropoxynicotinate；1-methylethyl 5-chloro-6-(1-methylethyloxy)-3-pyridinecarboxylate；5-chloro-6-isopropoxy-nicotinic acid isopropyl ester；5-chloro-6-isopropoxynicotinic acid isopropyl ester；propan-2-yl 5-chloro-6-propan-2-yloxypyridine-3-carboxylate
• CAS: 187401-46-3
• 化学式: C₁₂H₁₆ClNO₃
• 分子量: 257.717
• InChiKey: DZGWJMMDFNFBBH-UHFFFAOYSA-N

物化性质

• 沸点：
  319.9±37.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-methylethyl 5-chloro-6-[(1-methylethyl)oxy]-3-pyridinecarboxylate 在 吡啶 、 草酰氯 、 水 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 5.5h， 生成 5-(5-chloro-6-isopropoxypyridin-3-yl)-3-(5-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-1,2,4-oxadiazole trifluoroacetate
  参考文献：
  名称：

  Discovery of a Selective S1P₁ Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate

  摘要：

  Gilenya (fingolimod, FTY720) was recently approved by the U.S. FDA for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). It is a potent agonist of four of the five sphingosine 1-phosphate (SIP) G-protein-coupled receptors (S1P(1) and S1P(3-5)). It has been postulated that fingolimod's efficacy is due to S1P(1) agonism, while its cardiovascular side effects (transient bradycardia and hypertension) are due to S1P(3) agonism. We have discovered a series of selective S1P(1), agonists, which includes 3-[6- (5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-methyl- 3,4-dihydro-2(1H)-isoquinolinyl]propanoate, 20, a potent, S1P(3)-sparing, orally active S1P(1) agonist. Compound 20 is as efficacious as fingolimod in a collagen-induced arthritis model and shows excellent pharmacokinetic properties preclinically. Importantly, the selectivity of 20 against S1P(3) is responsible for an absence of cardiovascular signal in telemetered rats, even at high dose levels.

  DOI：

  10.1021/ml2000214
• 作为产物：
  描述：

  5,6-二氯烟酸 在 三甲基氯硅烷 、 potassium tert-butylate 作用下， 反应 55.0h， 生成 1-methylethyl 5-chloro-6-[(1-methylethyl)oxy]-3-pyridinecarboxylate
  参考文献：
  名称：

  PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

  摘要：

  本发明涉及式（D）的新吡啶衍生物、它们的制备方法以及它们作为药物活性化合物的用途。所述化合物特别是作为免疫调节剂发挥作用。式（I）中，A代表，其他取代基如权利要求中所定义。

  公开号：

  US20110212998A1

文献信息

• [EN] OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS D'INDAZOLE SUBSTITUÉS PAR OXADIAZOLE DESTINÉS À ÊTRE UTILISÉS COMME AGONISTES DU RÉCEPTEUR DE SPHINGOSINE-1-PHOSPHATE 1 (S1P1)
  申请人：GLAXO GROUP LTD

  公开号：WO2011072488A1

  公开（公告）日：2011-06-23

  Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.

  氧代唑取代吲唑衍生物的化学式（I）或其药用盐具有药理活性，公开了它们的制备方法、含有它们的药物组合物以及它们在治疗由S1P1受体介导的各种疾病中的用途。
• OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS
  申请人：Bailey James

  公开号：US20120283297A1

  公开（公告）日：2012-11-08

  Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.

  氧代唑取代吲唑衍生物的化学式（I）或其药用盐具有药理活性，公开了它们的制备方法、含有它们的药物组合物以及它们在治疗由S1P1受体介导的各种疾病中的用途。
• [EN] PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE PYRIDINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009024905A1

  公开（公告）日：2009-02-26

  The invention relates to novel pyridine derivatives of formula (I), their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituants are as defined in the claims.

  该发明涉及公式（I）的新型吡啶衍生物，其制备以及作为药用活性化合物的用途。所述化合物特别作为免疫调节剂。公式（I）中A代表，其他取代基如索引中定义。
• [EN] OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP)<br/>[FR] DÉRIVÉS D'OXADIAZOLE ACTIFS SUR LA SPHINGOSINE-1-PHOSPHATE (S1P)
  申请人：GLAXO GROUP LTD

  公开号：WO2009080725A1

  公开（公告）日：2009-07-02

  The present application discloses oxadiazole based compounds of Formula (I) active on sphingosine-1-phosphate (S1P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; R1 is up to two substituents independently selected from halogen, C(1-3)aIkoxy, C(1-3)flyoroalkyl, cyano, optionally substituted phenyl. C(1-3)fluoroalkoxy. C(1-6)alkyl and C(3-6)Cyctoalkyl; R2 is hydrogen, halogen or C(1-4)alkyl; B is a 7 membered saturated ring selected from the following: Formulae (a) (b) (c) R3 is hydrogen or (CH2)1-4MCO2H; R4 is hydrogen or C(1-3)alkyl optionally interrupted by oxygen;

  本申请披露了一种基于噁二唑的化合物，其化学式为（I），对神经酰胺-1-磷脂酸（S1P）具有活性，特别适用于治疗红斑狼疮。其中，A为苯基或5或6元杂环芳基环；R1为最多两个取代基，可独立选择自卤素、C（1-3）烷氧基、C（1-3）氟烷基、氰基、可选择取代的苯基、C（1-3）氟烷氧基、C（1-6）烷基和C（3-6）环烷基；R2为氢、卤素或C（1-4）烷基；B为以下选项中的7元饱和环之一：（a）（b）（c）；R3为氢或（CH2）1-4MCO2H；R4为氢或C（1-3）烷基，可由氧原子中断。
• COMPOUNDS
  申请人：HEER Jag Paul

  公开号：US20100174065A1

  公开（公告）日：2010-07-08

  The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

  本发明涉及具有药理活性的新型噁二唑衍生物，其制备方法，含有它们的药物组合物以及它们在治疗各种疾病中的用途。